Table 1.
Baseline characteristics of patients.
| Variables | Values | ||
| Median age (years), range | 71, 41-94 | ||
| Patients, N (%) | 39 (100) | ||
| Gender, n (%) |
|
||
|
|
Female | 10 (25.6) | |
| Male | 29 (74.4) | ||
| Comorbidities, n (%) |
|
||
|
|
Cardiovascular | 13 (33.3) | |
| Renal failure | 1 (2.6) | ||
| Chronic obstructive pulmonary disease | 1 (2.5) | ||
| Others | 12 (30.8) | ||
| None | 12 (30.8) | ||
| Location of cancer, n (%) |
|
||
|
|
Prostate | 23 (59) | |
| Lung | 12 (30.7) | ||
| Breast | 3 (7.7) | ||
| Bladder | 1 (2.6) | ||
| Stage, n (%) |
|
||
|
|
Metastatic | 23 (59) | |
| Localized | 12 (30.8) | ||
| Localized advanced | 2 (5.1) | ||
| Oligometastatic | 2 (5.1) | ||
| Clinical trial phase, n (%) |
|
||
|
|
I | 3 (7.7) | |
| I/II | 1 (2.6) | ||
| II | 2 (5.1) | ||
| II/III | 3 (7.7) | ||
| III | 30 (76.9) | ||
| Type of treatment, n (%) |
|
||
|
|
Chemotherapy and immunotherapy | 5 (12.8) | |
| Chemotherapy | 3 (7.7) | ||
| New generation of hormonotherapy | 11 (28.2) | ||
| Hormonotherapy and radiotherapy | 4 (10.2) | ||
| Hormonotherapy and targeted therapy | 3 (7.7) | ||
| Immunotherapy | 1 (2.6) | ||
| Immunotherapy and targeted therapy | 3 (7.7) | ||
| Targeted therapy | 3 (7.7) | ||
| Conjugated antibody | 1 (2.6) | ||
| Chemotherapy and hormonotherapy | 2 (5.1) | ||
| Other: adapted physical activity | 3 (7.7) | ||